ViiV Healthcare Says Health Canada Approved APRETUDE For Pre-Exposure Prophylaxis To Reduce Risk Of Sexually Acquired HIV
ViiV Healthcare Says Health Canada Approved APRETUDE For Pre-Exposure Prophylaxis To Reduce Risk Of Sexually Acquired HIV
ViiV Healthcare表示，加拿大衛生部批准了APRETUDE進行暴露前預防，以降低性獲得性感染艾滋病毒的風險
- Approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection in at-risk adults and adolescents aged 12 years and older, weighing at least 35 kg, including men who have sex with men, transgender women, and cisgender women.
- APRETUDE (cabotegravir extended release injectable suspension) is the first and only long-acting injectable PrEP treatment approved in Canada.
- Given as few as six times per year after initiation and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in 2 clinical trials.1
- The latest Canadian surveillance data shows that there were 1,833 new HIV diagnoses in 2022, a 24.9 per cent increase from 2021.2
- 獲准用於暴露前預防 (PrEP)，以降低年齡在 12 歲及以上、體重至少爲 35 kg 的高危成人和青少年的性獲得性 HIV 感染風險，包括與男性發生性關係的男性、變性女性和順性別女性。
- APRETUDE（卡博特韋緩釋注射懸浮液）是加拿大批准的第一種也是唯一一種長效可注射的PrEP療法。
- 在兩項臨床試驗中，啓動後每年僅給藥六次，在降低感染HIV風險方面，與每日口服PrEP方案（FTC/TDF片劑）相比，表現出優於每日口服PrEP方案（FTC/TDF片劑）的療效。1
- 加拿大最新的監測數據顯示，2022年新增了1,833例艾滋病毒診斷，比2021年增加了24.9％。2